Trial reportJournal of cosmetic dermatology2025
Enhancing Facial Rejuvenation Outcomes With a Novel Retinaldehyde-Based Cream: A Comparative Randomized Intra-Individual Study.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06942403 (In-use Tolerance and Efficacy Study Under Dermatological Control of an Anti-aging Cream), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In-use Tolerance and Efficacy Study Under Dermatological Control of an Anti-aging Cream (Split Face) Post Facial Superficial Rejuvenation Procedures, After re Epidermization
Who cites it
2 citing papers in PubMed.
- Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study.International journal of molecular sciences · 2026Trial
- Enhancing Facial Rejuvenation Outcomes With a Novel Retinaldehyde-Based Cream: A Comparative Randomized Intra-Individual Study.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMinimally-to-moderately invasive facial rejuvenation procedures, such as chemical peels, hyaluronic acid (HA) injections and fractional lasers, yield visible improvements in skin texture, tone and wrinkles; their long-term benefits can be optimized through a targeted anti-aging skincare regimen.
aimsThis controlled study aimed to evaluate the tolerability and efficacy of a cream containing three evidence-based active ingredients (retinaldehyde, niacinamide and haritaki fruit extract) to support and maintain the benefits of minimally to moderately invasive facial rejuvenation procedures.
methodsA monocentric, controlled, randomized, split-face study was conducted over a three-month period in subjects who had undergone one type of rejuvenation procedure, with assessments beginning after re-epidermization. Subjects were instructed to apply the test product on the randomized hemiface once daily.
resultsThis comparative controlled study, conducted under close dermatological supervision in 66 subjects who had undergone either chemical peels, HA injections, or fractional laser (n = 22 per group), demonstrated that the cream significantly improved multiple signs of aging. Throughout the entire study, compliance was very good. At 1 month (M1), wrinkles were significantly reduced, and the skin was significantly firmer and plumper, with improved texture. Skin tone homogeneity and radiance were significantly enhanced as of M1 (and M2 for skin smoothness) versus the control hemiface.
conclusionRegular application of the study product, which contains retinaldehyde, niacinamide, and haritaki fruit extract, yielded significantly visible anti-aging results already at 1 month compared with the control, with very good skin tolerance. It can be used to maximize and maintain the benefits of rejuvenation procedures and promote long-term skin health.
trial registrationClinicalTrials.gov identifier: NCT06942403.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.